Cargando…

Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?

Over the last decade, non-alcoholic fatty liver disease (NAFLD) has overtaken alcohol as the leading cause of cirrhosis in the Western world. There remains to be a licensed pharmacological treatment for NAFLD. Weight loss is advised for all patients with NAFLD. Many patients however, struggle to los...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandour, Mandour Omer, El-Hassan, Mohammed, Elkomi, Rawan M, Oben, Jude A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521460/
https://www.ncbi.nlm.nih.gov/pubmed/36185721
http://dx.doi.org/10.4254/wjh.v14.i9.1704
_version_ 1784799842982166528
author Mandour, Mandour Omer
El-Hassan, Mohammed
Elkomi, Rawan M
Oben, Jude A
author_facet Mandour, Mandour Omer
El-Hassan, Mohammed
Elkomi, Rawan M
Oben, Jude A
author_sort Mandour, Mandour Omer
collection PubMed
description Over the last decade, non-alcoholic fatty liver disease (NAFLD) has overtaken alcohol as the leading cause of cirrhosis in the Western world. There remains to be a licensed pharmacological treatment for NAFLD. Weight loss is advised for all patients with NAFLD. Many patients however, struggle to lose the recommended weight with lifestyle modification alone. Many drugs have either failed to show significant improvement of steatosis or are poorly tolerated. Bariatric surgery has been shown to reduce liver steatosis and regress liver fibrosis. The pathophysiology is not fully understood, however recent evidence has pointed towards changes in the gut microbiome following surgery. Novel endoscopic treatment options provide a minimally invasive alternative for weight loss. Randomised controlled trials are now required for further clarification.
format Online
Article
Text
id pubmed-9521460
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-95214602022-09-30 Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future? Mandour, Mandour Omer El-Hassan, Mohammed Elkomi, Rawan M Oben, Jude A World J Hepatol Minireviews Over the last decade, non-alcoholic fatty liver disease (NAFLD) has overtaken alcohol as the leading cause of cirrhosis in the Western world. There remains to be a licensed pharmacological treatment for NAFLD. Weight loss is advised for all patients with NAFLD. Many patients however, struggle to lose the recommended weight with lifestyle modification alone. Many drugs have either failed to show significant improvement of steatosis or are poorly tolerated. Bariatric surgery has been shown to reduce liver steatosis and regress liver fibrosis. The pathophysiology is not fully understood, however recent evidence has pointed towards changes in the gut microbiome following surgery. Novel endoscopic treatment options provide a minimally invasive alternative for weight loss. Randomised controlled trials are now required for further clarification. Baishideng Publishing Group Inc 2022-09-27 2022-09-27 /pmc/articles/PMC9521460/ /pubmed/36185721 http://dx.doi.org/10.4254/wjh.v14.i9.1704 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Mandour, Mandour Omer
El-Hassan, Mohammed
Elkomi, Rawan M
Oben, Jude A
Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title_full Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title_fullStr Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title_full_unstemmed Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title_short Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
title_sort non-alcoholic fatty liver disease: is surgery the best current option and can novel endoscopy play a role in the future?
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521460/
https://www.ncbi.nlm.nih.gov/pubmed/36185721
http://dx.doi.org/10.4254/wjh.v14.i9.1704
work_keys_str_mv AT mandourmandouromer nonalcoholicfattyliverdiseaseissurgerythebestcurrentoptionandcannovelendoscopyplayaroleinthefuture
AT elhassanmohammed nonalcoholicfattyliverdiseaseissurgerythebestcurrentoptionandcannovelendoscopyplayaroleinthefuture
AT elkomirawanm nonalcoholicfattyliverdiseaseissurgerythebestcurrentoptionandcannovelendoscopyplayaroleinthefuture
AT obenjudea nonalcoholicfattyliverdiseaseissurgerythebestcurrentoptionandcannovelendoscopyplayaroleinthefuture